FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Clinical Trial Begins to Test GLP-1 Agonist Effects on Neuro-reproductive Function in Obese Adolescent Females With PCOS [NCT07169136]
研究ライブラリに戻る

Clinical Trial Begins to Test GLP-1 Agonist Effects on Neuro-reproductive Function in Obese Adolescent Females With PCOS [NCT07169136]

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Clinical Trial Begins to Test GLP-1 Agonist Effects on Neuro-reproductive Function in Obese Adolescent Females With PCOS [NCT07169136]

A new clinical trial is exploring the potential benefits of glucagon-like peptide-1 (GLP-1) agonist therapy for obese adolescent females with polycystic ovary syndrome (PCOS). The study, registered on ClinicalTrials.gov under identifier NCT07169136 and sponsored by Nemours Children's Clinic, aims to investigate the effects of GLP-1 receptor agonists on neuro-reproductive function in this specific patient group.

The prevalence of childhood obesity has surged over the past four decades, disproportionately affecting adolescent girls, especially those from racial or ethnic minority backgrounds. This rise in obesity rates is particularly concerning given its impact on pubertal development and reproductive health. Normal puberty onset and progression rely heavily on a well-functioning hypothalamic-pituitary-gonadal (HPG) axis, which can be disrupted by metabolic disorders like PCOS.

Key Details

The trial will focus on how GLP-1 receptor agonists might help regulate the HPG axis in obese adolescent females with PCOS. These peptides are known for their role in glucose regulation and weight management but have also shown potential in improving reproductive health outcomes. The study aims to uncover whether these compounds can effectively manage symptoms associated with both obesity and PCOS, such as irregular menstrual cycles and hormonal imbalances.

GLP-1 agonists work by mimicking the actions of natural GLP-1, which is produced in the gut and helps regulate blood sugar levels and appetite. By targeting this pathway, researchers hope to address not only metabolic issues but also reproductive health concerns that arise from obesity and PCOS. This dual approach could offer a comprehensive treatment option for adolescent girls struggling with these conditions.

Key Takeaways

  • GLP-1 Agonists May Improve Neuro-Reproductive Function: The study seeks to determine if GLP-1 agonists can positively impact the HPG axis in obese adolescents with PCOS.
  • Addressing Dual Concerns of Obesity and PCOS: Researchers aim to explore how these peptides might manage both metabolic issues and reproductive health concerns simultaneously.
  • Potential for Broader Application: If successful, this research could pave the way for GLP-1 agonists as a viable treatment option for other patient groups facing similar challenges.
  • Important Step Forward in Peptide Therapy Research: This trial represents significant progress in understanding how peptide therapies can address complex health issues affecting young people.

What This Means

For the peptide community, this study marks an important step forward in exploring the therapeutic potential of GLP-1 agonists beyond their well-known benefits for diabetes and weight management. By investigating their effects on neuro-reproductive function, researchers are opening up new avenues for treating multifaceted conditions like PCOS and obesity in adolescents.

As more research emerges, peptide therapy could become a cornerstone treatment approach for managing these complex health issues, offering hope to patients and clinicians alike. The findings from this trial will contribute valuable insights into the broader landscape of peptide-based treatments and their applications across various medical fields.

---

Source: ClinicalTrials.gov — Published 2026-11-17

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。